Stuttgart - Delayed Quote EUR

9LB.SG,0P0001L9BB,0 (9LB.SG)

55.00

+0.50

+(0.92%)

At close: July 23 at 10:00:00 PM GMT+2

Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension

Stock futures are mixed, signaling a potential pause following Monday’s rally driven by optimism over a temporary U.S.-China trade deal. In corporate news, UnitedHealth Group shares plunged 10% after CEO Andrew Witty stepped down, with former CEO Stephen Hemsley stepping in. The company also suspended its outlook due to rising medical costs. Bitcoin has regained value above $103,800, aligning with Coinbase’s rise after inclusion into the S&P 500. In pre-market trading, S&P 500 futures were fla

TipRanks 2 days ago

UA

UAA

UNH
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia’s TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31

GlobeNewswire 3 days ago

LEGN
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A repl

GlobeNewswire 17 days ago

LEGN
Exploring US High Growth Tech Stocks

Over the last 7 days, the United States market has experienced a 3.0% drop, although it has risen by 4.6% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks requires careful consideration of their innovation potential and ability to capitalize on emerging trends within a dynamic market environment.

Simply Wall St. 29 days ago

LEGN

TGTX

NFLX
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks last month

GLPG

GLPGF

PTCT
Legend Biotech Full Year 2024 Earnings: Beats Expectations

Legend Biotech ( NASDAQ:LEGN ) Full Year 2024 Results Key Financial Results Revenue: US$627.2m (up 120% from FY 2023...

Simply Wall St. 2 months ago

LEGN
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at a Novartis production facilitySpain's national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide fin

GlobeNewswire 2 months ago

LEGN
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

SOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 11, 2025, to review fourth-quarter and full-year 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s quarter and fiscal year performance. Investors and other interested parties may join the live audio webcast of the call

GlobeNewswire 2 months ago

LEGN
High Growth Tech Stocks To Watch In February 2025

The United States market has experienced a positive trend, rising 1.2% over the last week and climbing 24% in the past year, with earnings anticipated to grow by 15% annually in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Simply Wall St. 2 months ago

LEGN

ZLAB

TTWO
High Growth Tech Stocks to Watch in January 2025

Over the last week, the United States market saw a 3.1% increase, contributing to a 24% climb over the past year, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks that align with these optimistic projections can be crucial for investors looking to capitalize on emerging opportunities in this dynamic sector.

Simply Wall St. 3 months ago

KRYS

LEGN

SLNO
Exploring 3 High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 2.7% drop, yet it remains up by 23% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong potential for innovation and adaptability in response to evolving market conditions.

Simply Wall St. 4 months ago

MNKD

RYTM

LEGN
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT. Investors and other interested parties can access the live audio webcast through the Investor Relations section of L

GlobeNewswire 4 months ago

LEGN
Legend Biotech’s CARVYKTI® Boosts Myeloma Treatment Success

Legend Biotech (LEGN) has released an update. Legend Biotech’s CARVYKTI® has demonstrated a significant improvement in minimal residual disease negativity for multiple myeloma patients compared to standard treatments, according to recent phase 3 trial results. The study highlights CARVYKTI®’s potential as a transformative cell therapy, achieving an 89% MRD-negative rate in treated patients, which could enhance progression-free and overall survival outcomes. This promising data may bolster invest

TipRanks 5 months ago

LEGN
$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI® after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 monthsResults add to the overall survival (OS) benefit recently reported making CARVYKTI® the first and only cell therapy to significantly extend OS versus standard therapies in multiple myelomaLandmark Phase 3 CARTITUDE-4 study data featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual M

GlobeNewswire 5 months ago

LEGN
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.

Investor's Business Daily 5 months ago

ACLX

JNJ

LEGN
High Growth Tech Stocks in the United States to Watch

Over the last 7 days, the United States market has dropped by 1.0%, but it has experienced a robust growth of 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that can capitalize on technological advancements and maintain strong performance despite short-term market fluctuations.

Simply Wall St. 5 months ago

ORCL

LEGN

GLW
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Shareholders might have noticed that Legend Biotech Corporation ( NASDAQ:LEGN ) filed its third-quarter result this...

Simply Wall St. 5 months ago

LEGN
Legend Biotech Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Legend Biotech ( NASDAQ:LEGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$160.2m (up 67% from 3Q...

Simply Wall St. 5 months ago

LEGN
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) updates: Net trade sales of approximately $286 million, representing operational growth of 87.6% year-over-year and 53.2% quarter-over-quarterFirst and only cell therapy clinically shown to significantly extend overall survival versus standard therapies in multiple myeloma patients as early as second line; presented CARTITUDE-4 three-year follow-up data at the International Myeloma Society Annual MeetingInitiated commercial production at Obelisc f

GlobeNewswire 5 months ago

LEGN
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as

GlobeNewswire 6 months ago

LEGN

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

9LB.SG,0P0001L9BB,0 (9LB.SG)

Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

Exploring US High Growth Tech Stocks

Biotech stocks slide as Marks resignation seen being negative for sector

Legend Biotech Full Year 2024 Earnings: Beats Expectations

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

High Growth Tech Stocks To Watch In February 2025

High Growth Tech Stocks to Watch in January 2025

Exploring 3 High Growth Tech Stocks In The United States

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Legend Biotech’s CARVYKTI® Boosts Myeloma Treatment Success

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

High Growth Tech Stocks in the United States to Watch

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Legend Biotech Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition